Taro Pharmaceutical Industries (TARO) Downgraded by ValuEngine
Taro Pharmaceutical Industries (NYSE:TARO) was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating in a report issued on Monday.
Several other equities research analysts also recently weighed in on TARO. Zacks Investment Research downgraded Taro Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a report on Thursday, August 16th. TheStreet raised Taro Pharmaceutical Industries from a “c+” rating to a “b-” rating in a report on Monday, June 4th. Finally, HC Wainwright reissued a “buy” rating and issued a $120.00 price objective on shares of Taro Pharmaceutical Industries in a report on Friday, August 10th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and one has given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $124.50.
Shares of TARO stock traded down $0.79 during trading hours on Monday, hitting $98.63. The stock had a trading volume of 19,000 shares, compared to its average volume of 65,627. The company has a market capitalization of $3.92 billion, a P/E ratio of 15.96 and a beta of 0.48. Taro Pharmaceutical Industries has a twelve month low of $93.01 and a twelve month high of $128.46.
Hedge funds have recently bought and sold shares of the company. FMR LLC lifted its holdings in shares of Taro Pharmaceutical Industries by 1.6% during the second quarter. FMR LLC now owns 655,851 shares of the company’s stock worth $75,875,000 after purchasing an additional 10,562 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Taro Pharmaceutical Industries by 9.8% during the second quarter. Renaissance Technologies LLC now owns 287,000 shares of the company’s stock worth $33,203,000 after purchasing an additional 25,600 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Taro Pharmaceutical Industries by 8.5% during the first quarter. Dimensional Fund Advisors LP now owns 260,672 shares of the company’s stock worth $25,739,000 after purchasing an additional 20,407 shares during the period. Acadian Asset Management LLC lifted its holdings in shares of Taro Pharmaceutical Industries by 136.8% during the second quarter. Acadian Asset Management LLC now owns 235,930 shares of the company’s stock worth $27,295,000 after purchasing an additional 136,287 shares during the period. Finally, Freestone Capital Holdings LLC lifted its holdings in shares of Taro Pharmaceutical Industries by 14.7% during the first quarter. Freestone Capital Holdings LLC now owns 166,748 shares of the company’s stock worth $16,464,000 after purchasing an additional 21,392 shares during the period. 10.40% of the stock is owned by institutional investors and hedge funds.
Taro Pharmaceutical Industries Company Profile
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories.
Featured Story: Google Finance Portfolio Workaround
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.